New drug combo aims to shrink lung tumors enough for radiation
NCT ID NCT04765709
First seen Jan 04, 2026 · Last updated May 24, 2026 · Updated 23 times
Summary
This study tested whether adding an immunotherapy drug (durvalumab) to standard chemotherapy before radiation could help people with large, inoperable stage III lung cancer become eligible for radiation therapy. The goal was to shrink tumors enough to safely deliver radiation. The trial was stopped early, but the approach aimed to improve outcomes for patients who currently have few options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER (STAGE III) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, 20133, Italy
-
Gustave Roussy Institute
Paris, France
-
Vall d'Hebron Barcelona Hospital
Barcelona, Spain
Conditions
Explore the condition pages connected to this study.